Nephrology Stocks
Specialized therapeutic and diagnostic providers in this sector focus on the high-cost management of chronic kidney disease (CKD), end-stage renal disease (ESRD), and rare glomerular pathologies. Revenue models range from recurring service fees for outpatient dialysis to high-margin orphan drug commercialization targeting inflammatory and autoimmune renal triggers.
As of Oct 23, 2026, Nephrology has 23 US-listed companies worth $174B combined. The median member moved +1.1% over the past week; REVB led at +681.9% and NUWE trailed at -41.3%.
Companies in Nephrology
- VRTX – Vertex Pharmaceuticals Inc, $136B
- DVA – DaVita HealthCare Partners Inc, $11.9B
- FMS – Fresenius Medical Care Corporation, $11.8B
- TVTX – Travere Therapeutics Inc, $4.9B
- VERA – Vera Therapeutics Inc, $2.2B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- JBIO – Jade Biosciences, Inc., $853M
- ARDX – Ardelyx Inc, $842M
- PROK – ProKidney Corp., $695M
- CLYM – Climb Bio Inc, $592M
- CRMD – CorMedix Inc, $576M
- AKBA – Akebia Ther, $171M
- UNCY – Unicycive Therapeutics Inc, $92M
- OM – Outset Medical Inc, $79.1M
- TLPH – Talphera Inc., $55M
- ELOX – Eloxx Pharmaceuticals, Inc., $53M
- RMTI – Rockwell Medical Inc, $31.6M
- ICU – SeaStar Medical Holding Corporation, $15.3M
- REVB – Revelation Biosciences Inc, $3.3M
- XRTX – XORTX Therapeutics Inc, $2.3M
- NUWE – Nuwellis Inc, $2M
- ZVSA – ZyVersa Therapeutics Inc., $647,673